Truist cuts Doximity stock rating on softer growth outlook

Truist downgraded Doximity to Hold from Buy and cut its price target to $29 from $37, citing reduced revenue growth visibility, structural risks, and expected FY2027 growth below consensus. The firm also pointed to CFO resignation, multiple compression in healthcare IT, and rising competition from AI-native platforms like OpenEvidence. Shares trade at $24.71, about 67% below the 52-week high of $76.51, and are down 63.66% over the past six months.

Analysis

DOCS is shifting from a “quality compounder” multiple to a scrutiny trade: when revenue visibility weakens and the market starts questioning whether the spend pool itself is decelerating, the stock stops trading on TAM and starts trading on budget durability. The key second-order effect is that AI-native clinical search tools do not need to fully displace Doximity to hurt the equity; they only need to cap incremental wallet share growth, which compresses valuation before any outright fundamental break shows up.

The CFO departure matters less as a governance headline than as a timing problem for the next reset of expectations. In a re-rating regime, the absence of a clean financial steward increases the odds management chooses conservatism on the next guide, which can create a self-reinforcing downgrade cycle: lower guide, lower estimates, lower multiple, then further skepticism around the quality of bookings. That dynamic tends to play out over 1-2 quarters, not years, and is especially punitive when sell-side models still anchor to pre-downshift growth assumptions.

The contrarian point is that this is now a very crowded bearish setup: the stock has already de-rated sharply, and if the company can merely show stability in pharma ad budgets plus no further evidence of share loss, the short thesis loses urgency. The more durable bear case is not a one-quarter miss but evidence that the platform’s monetization rate is saturating while AI competitors expand usage curves; that would justify another leg lower even without a dramatic top-line deceleration.

For investors, the cleanest expression is not an outright short into the report cycle, but a defined-risk structure that benefits from volatility compression after an expected conservative guide. The risk/reward improves if the next 30-60 days bring analyst estimate cuts and no positive read-through from pharma spend surveys; if those cut revisions stop, the downside momentum likely stalls before the market can reprice to a true low-teens EBITDA multiple.

Key Decisions for Investors

• Buy DOCS puts or put spreads into the next earnings call, targeting a 30-60 day horizon; risk/reward favors a downside air pocket if management guides conservatively and analysts keep cutting FY27 numbers.
• Pair trade: short DOCS / long a profitable healthcare IT name with more visible budget exposure, for a 1-2 quarter horizon; this isolates multiple compression and competitive pressure while reducing market beta.
• If DOCS stabilizes after earnings, use any post-print rally to initiate a smaller short; the better entry is a failed bounce rather than weakness into the event, because the stock is already heavily de-rated.
• Avoid chasing the bullish valuation argument unless there is clear evidence that pharma digital marketing budgets are reaccelerating; absent that, the upside is capped by continued multiple compression.
• For event-driven accounts, consider a DOCS strangle only if implied volatility remains subdued; this captures either a guide-down downside gap or a relief rally if guidance is merely conservative but not worse.